Genomic Health, Inc. (GHDX) Insider James J. Vaughn Sells 3,000 Shares

Share on StockTwits

Genomic Health, Inc. (NASDAQ:GHDX) insider James J. Vaughn sold 3,000 shares of the stock in a transaction dated Thursday, February 7th. The stock was sold at an average price of $77.42, for a total transaction of $232,260.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

James J. Vaughn also recently made the following trade(s):

  • On Tuesday, January 8th, James J. Vaughn sold 3,000 shares of Genomic Health stock. The stock was sold at an average price of $67.06, for a total transaction of $201,180.00.
  • On Thursday, December 6th, James J. Vaughn sold 3,000 shares of Genomic Health stock. The stock was sold at an average price of $75.30, for a total transaction of $225,900.00.

GHDX stock traded up $1.73 during trading on Monday, hitting $80.42. 258,832 shares of the company’s stock traded hands, compared to its average volume of 332,858. The firm has a market cap of $2.87 billion, a price-to-earnings ratio of 8,042.00 and a beta of 0.88. Genomic Health, Inc. has a 1 year low of $30.04 and a 1 year high of $92.18.

A number of analysts recently weighed in on GHDX shares. Canaccord Genuity reissued a “buy” rating and issued a $82.00 price objective (up from $70.00) on shares of Genomic Health in a research report on Wednesday, November 7th. BidaskClub lowered shares of Genomic Health from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 18th. ValuEngine lowered shares of Genomic Health from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 11th. Zacks Investment Research reaffirmed a “hold” rating on shares of Genomic Health in a research report on Tuesday, November 13th. Finally, Raymond James assumed coverage on shares of Genomic Health in a research report on Tuesday, October 23rd. They set a “market perform” rating on the stock. Nine research analysts have rated the stock with a hold rating, two have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Genomic Health has a consensus rating of “Hold” and a consensus target price of $58.50.

A number of hedge funds have recently modified their holdings of GHDX. Royce & Associates LP increased its holdings in Genomic Health by 22.8% during the fourth quarter. Royce & Associates LP now owns 1,473 shares of the medical research company’s stock valued at $95,000 after buying an additional 273 shares during the period. Advisor Group Inc. boosted its stake in Genomic Health by 34.9% in the fourth quarter. Advisor Group Inc. now owns 1,995 shares of the medical research company’s stock valued at $129,000 after acquiring an additional 516 shares in the last quarter. Pacer Advisors Inc. acquired a new stake in Genomic Health in the third quarter valued at approximately $171,000. Quantamental Technologies LLC acquired a new stake in Genomic Health in the fourth quarter valued at approximately $180,000. Finally, Trexquant Investment LP acquired a new stake in Genomic Health in the third quarter valued at approximately $202,000. 90.09% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This article was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/4144439/genomic-health-inc-ghdx-insider-james-j-vaughn-sells-3000-shares.html.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Recommended Story: What is the S&P 500 Index?

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

InZinc Mining  Shares Up 28.6%
InZinc Mining Shares Up 28.6%
Cellular Biomedicine Group  Releases  Earnings Results
Cellular Biomedicine Group Releases Earnings Results
Cincinnati Financial Co.  Director Dirk J. Debbink Acquires 351 Shares
Cincinnati Financial Co. Director Dirk J. Debbink Acquires 351 Shares
Insider Selling: Paratek Pharmaceuticals Inc  Director Sells 3,375 Shares of Stock
Insider Selling: Paratek Pharmaceuticals Inc Director Sells 3,375 Shares of Stock
PS Business Parks  Posts  Earnings Results, Misses Expectations By $0.48 EPS
PS Business Parks Posts Earnings Results, Misses Expectations By $0.48 EPS
Yamana Gold Inc.  Senior Officer Richard Campbell Sells 12,776 Shares of Stock
Yamana Gold Inc. Senior Officer Richard Campbell Sells 12,776 Shares of Stock


Leave a Reply

© 2006-2019 Ticker Report